Collaboration in Development of New Drugs

• 成果类型: Article
• 署名作者: Tian, Zhili; Gurnani, Haresh; Xu, Yi
• 署名单位: Coastal Carolina University; Wake Forest University; University System of Maryland; University of Maryland College Park
• 刊物名称: PRODUCTION AND OPERATIONS MANAGEMENT
• ISSN/ISSBN: 1059-1478
• DOI: 10.1111/poms.13377
• 发表日期: 2021
• 页码: 3943-3966
• 关键词: collaboration in drug development; new drug development management; new drug development competition; clinical trials; R&D investment

摘要

The development of a new drug is costly and uncertain. As such, pharmaceutical firms often collaborate to develop new drugs. We examine the conditions under which firms should collaborate rather than compete in new drug development. We model the collaboration vs. competition decision problem for two firms using a game-theoretic model and derive the collaboration conditions. Our study demonstrates that development cost and uncertainties in drug treatment efficacy and safety and patient enrollment drive the collaboration or competition decision for firms. We establish conditions based on probabilities of success of drug development, cost rates, and potential market shares under which the firms should collaborate, and show that there exist scenarios under which the firms actually collaborate on the lower efficacy drug. As such, firms need to take into consideration various factors such as the probability of success, the potential market share, and the development cost of each competing drug when determining whether to collaborate or compete in developing new drugs. Finally, we apply our analytical model to illustrate a case study involving collaboration between Bristol-Myers Squibb and Pfizer.